<SEC-DOCUMENT>0001628280-25-013875.txt : 20250319
<SEC-HEADER>0001628280-25-013875.hdr.sgml : 20250319
<ACCEPTANCE-DATETIME>20250319170729
ACCESSION NUMBER:		0001628280-25-013875
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250319
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20250319
DATE AS OF CHANGE:		20250319

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		25753607

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>cpix-20250319.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:13b9bc89-ef3b-478e-b901-8a57c671430d,g:31c95f9c-d6b6-4398-8ff0-d9ad9012d247,d:bf3afebcc1134b24bf513502b5a5a011-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>cpix-20250319</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001087294</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-23">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="cpix-20250319.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001087294</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-19</xbrli:startDate><xbrli:endDate>2025-03-19</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ibf3afebcc1134b24bf513502b5a5a011_1"></div><div style="min-height:29.25pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:174%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">March 19, 2025 (<ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">March 19, 2025</ix:nonNumeric>)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.057%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.059%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Tennessee</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-33637</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">62-1765329</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">1600 West End Avenue, Suite 1300</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Nashville</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-9">Tennessee</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">37203</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(Address of Principal Executive Offices)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">615</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">255-0068</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt:fixed-false" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">CPIX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ibf3afebcc1134b24bf513502b5a5a011_4"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.01 &#160;&#160;&#160;&#160;Other Events</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2025, Cumberland Pharmaceuticals Inc. (&#8220;Cumberland&#8221;) announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrophy Association (MDA) Clinical &amp; Scientific Conference in Dallas. The trial demonstrated significant cardiac benefits for patients with Duchenne muscular dystrophy (DMD), potentially addressing the leading cause of death in this devastating disease.</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of the release is furnished as </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="dmdpresentationatmdareleas.htm">Exhibit 99.1.</a></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.210%"><tr><td style="width:1.0%"/><td style="width:22.511%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.893%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.296%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dmdpresentationatmdareleas.htm">99.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="dmdpresentationatmdareleas.htm">Press release dated March 19, 2025</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;text-align:justify"><span><br/></span></div><div id="ibf3afebcc1134b24bf513502b5a5a011_7"></div><div style="margin-top:11.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:11.25pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:16.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.386%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumberland Pharmaceuticals Inc.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: March 19, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John Hamm</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dmdpresentationatmdareleas.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ib9f6c398600d43179f316d8ea325843c_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:8pt;margin-top:18pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:90px;margin-bottom:5pt;vertical-align:text-bottom;width:394px"></div><div style="margin-top:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:125%">FIGHT DMD Trial Results </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:125%">Selected for Late-Breaking Presentation </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-style:italic;font-weight:700;line-height:125%">at MDA Clinical &#38; Scientific Conference</font></div><div style="margin-bottom:18pt;margin-top:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-style:italic;font-weight:400;line-height:125%">Ifetroban demonstrated significant 5.4% improvement in cardiac function </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NASHVILLE, Tenn. (March 19, 2025)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Cumberland Pharmaceuticals Inc. (Nasdaq&#58; CPIX), a specialty pharmaceutical company with development efforts focused on rare diseases, today announced that results from its Phase 2 FIGHT DMD clinical trial were selected for a late-breaking presentation at the Muscular Dystrophy Association (MDA) Clinical &#38; Scientific Conference in Dallas. The trial demonstrated significant cardiac benefits for patients with Duchenne muscular dystrophy (DMD), potentially addressing the leading cause of death in this devastating disease.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The presentation, delivered today by Dr. John Jerry Parent, highlighted the breakthrough findings from Cumberland&#8217;s study of ifetroban in DMD heart disease. For the abstract presented at the meeting, please see </font><font style="color:#477886;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MDA website. </font><font style="color:#467886;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 2 FIGHT DMD trial demonstrated that high-dose ifetroban treatment resulted in a 3.3% improvement in left ventricular ejection fraction (LVEF) compared to placebo. When compared with propensity-matched natural history controls, the difference was even more pronounced, with high-dose treatment providing a significant 5.4% overall improvement in LVEF, as control patients experienced a 3.6% decline in LVEF. This improvement in cardiac function could translate to meaningful benefits in quality of life and survival for DMD patients. The complete presentation slides are now available on Cumberland&#8217;s website.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;The enthusiastic response from MDA conference attendees reinforces the importance of our work in targeting DMD-related heart disease,&#8221; said John Jerry Parent, MD, Associate Professor of Clinical Pediatrics and Medical Director of the Pediatric Heart Transplant at Indiana University School of Medicine and Site Investigator at Riley Children&#8217;s Hospital for the FIGHT DMD trial. &#8220;These findings represent a potential paradigm shift in how we approach cardiac complications in DMD patients.&#8221;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;We are honored that the MDA recognized the significance of our FIGHT DMD trial by selecting it for a late-breaking presentation,&#8221; said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. &#8220;This platform allowed us to share our promising results with the global DMD community, including leading researchers, clinicians and patient advocates who are working tirelessly to improve outcomes for those affected by this devastating disease.&#8221;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;These results offer hope to thousands of families affected by DMD,&#8221; said Sharon Hesterlee, PhD, Chief Research Officer, MDA. &#8220;While current therapies focus on preserving muscle function, addressing the cardiac complications of DMD remains an urgent unmet need. Cumberland&#8217;s work with ifetroban represents a critical step forward in potentially extending and improving the lives of DMD patients.&#8221;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ifetroban, an oral thromboxane receptor antagonist, has received both </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rare Pediatric Disease Designation </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the FDA for DMD-related heart disease. </font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland has secured a growing portfolio of patents with claims associated with the product for this DMD indication. Next steps include further data analysis and completion of a full study report in preparation for an end-of-Phase-2 meeting with the FDA to determine next steps associated with the product&#8217;s development and commercialization.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information about the FIGHT DMD trial, please visit www.fightdmdtrial.com.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">About Duchenne muscular dystrophy (DMD)</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DMD is a rare and incurable pediatric disease caused by mutations in the gene encoding dystrophin, a protein critical for muscle function, including the heart. Patients with DMD slowly lose muscle function, resulting in the inability to walk, difficulty breathing and heart failure. While current treatments can help manage some DMD symptoms, there are no approved therapies specifically targeting DMD-related heart disease, highlighting a critical unmet medical need. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">About ifetroban</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ifetroban is a once-daily oral medication that works by blocking the thromboxane receptor, which plays a key role in inflammation and fibrosis. The drug has received both </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drug Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rare Pediatric Disease Designation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the FDA, highlighting its potential significance in treating this devastating condition. If approved, ifetroban would be the first therapy specifically indicated for DMD-related heart disease.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A previous study conducted at Vanderbilt University Medical Center demonstrated that ifetroban is protective against cardiomyopathy in several preclinical models of muscular dystrophy. The results of that study were published in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Journal of the American Heart Association</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (West 2019). Based on those promising results, Cumberland Pharmaceuticals became the first recipient of an FDA Office of Orphan Products Development clinical trial grant for DMD, funding the development of this Phase 2 clinical trial.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">References&#58;</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soslow JH, Xu M, Slaughter JC, et al. Cardiovascular Measures of All-Cause Mortality in Duchenne Muscular Dystrophy. Circ Heart Fail. 2023 Aug&#59;16(8)&#58;e010040. doi&#58; 10.1161&#47;CIRCHEARTFAILURE.122.010040. Epub 2023 Jun 8. PMID&#58; 37288563&#59; PMCID&#58; PMC10524475.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">West JD, Galindo CL, Kim K, et al. Antagonism of the thromboxane-prostanoid receptor as a potential therapy for cardiomyopathy of muscular dystrophy. J Am Heart Assoc. 2019&#59;8(21)&#58;e011902. doi&#58; 10.1161&#47;JAHA.118.011902. </font></div><div style="margin-top:8pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">About Cumberland Pharmaceuticals</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cumberland Pharmaceuticals </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is the largest biopharmaceutical company founded and headquartered in Tennessee. The company is focused on providing unique products that improve the quality of patient care. Cumberland develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. </font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland&#8217;s portfolio of FDA-approved brands includes&#58;</font></div><div style="margin-top:8pt;padding-left:54pt;padding-right:20.9pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Acetadote</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">acetylcysteine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of acetaminophen poisoning&#59;</font></div><div style="margin-top:8pt;padding-left:54pt;padding-right:21pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Caldolor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ibuprofen</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of pain and fever&#59;</font></div><div style="margin-top:8pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Kristalose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">lactulose</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) oral, a prescription laxative, for the treatment of constipation&#59;</font></div><div style="margin-top:8pt;padding-left:54pt;padding-right:21pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Sancuso</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">granisetron</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment&#59;</font></div><div style="margin-top:8pt;padding-left:54pt;padding-right:21pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vaprisol</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">conivaptan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia&#59; and</font></div><div style="margin-top:8pt;padding-left:54pt;padding-right:20.9pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Vibativ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">telavancin</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.               </font></div><div style="margin-top:8pt;padding-right:12.95pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to this Duchenne muscular dystrophy program, the company also has Phase 2 clinical studies underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis and Idiopathic Pulmonary Fibrosis.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information on Cumberland&#8217;s approved products, including full prescribing information, please visit the individual product websites, which can be found on the company&#8217;s website&#58; www.cumberlandpharma.com.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Forward-Looking Statements</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland&#8217;s current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the company&#8217;s intent, belief or expectations, and can be identified by the use of terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;estimate,&#8221; &#8220;should,&#8221; &#8220;seek,&#8221; &#8220;anticipate,&#8221; &#8220;look forward&#8221; and other comparable terms or the negative thereof. As with any business, all phases of Cumberland&#8217;s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland&#8217;s operation results. These factors include macroeconomic conditions, including rising interest rates and inflation, competition, an inability of manufacturers to produce Cumberland&#8217;s products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the company&#8217;s control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), as well as the company&#8217;s other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SOURCE&#58; Cumberland Pharmaceuticals Inc.</font></div><div style="margin-top:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Contact&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Media Contact&#58;</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shayla Simpson&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Molly Aggas</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumberland Pharmaceuticals&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Dalton Agency</font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(615) 255-0068&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(704) 641-6641</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>cpix-20250319.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:13b9bc89-ef3b-478e-b901-8a57c671430d,g:31c95f9c-d6b6-4398-8ff0-d9ad9012d247-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:cpix="http://cumberlandpharma.com/20250319" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cumberlandpharma.com/20250319">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20250319_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="cpix-20250319_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cpix-20250319_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:13b9bc89-ef3b-478e-b901-8a57c671430d,g:31c95f9c-d6b6-4398-8ff0-d9ad9012d247-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_88167634-94d9-4006-896c-ac0caa33c3c2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_30f9a09c-8735-4eef-9366-024db23986b7_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_5fa120fc-57fe-4f06-990b-8f9f4d83aaa4_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8c33d4e5-c8b0-4d62-b732-6f4967d8b190_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_66714772-e4e1-42bc-8b79-bb034d1e1b88_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_ff149102-e833-45d1-a619-1668645eedef_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a021ce64-bfc8-4c17-97df-3dc70c319b00_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_92a4c326-0c88-4493-8c5f-f589ad2e2a02_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_0d7bb2ee-c89b-46bc-abd8-9a91c244787a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_674735f5-732c-425d-bd87-18890812a3da_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_fef57c14-e2a0-4c24-9a84-739bd2a9a208_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_45d535b7-048c-4d4b-94a8-131e2a14707b_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4de83ae0-6afe-4aa1-868e-c192f85b3a0c_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_9e3f03ad-f0a4-4dff-9b70-0a60d03a0a50_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_7bf77e91-432e-45c9-9a28-03ca76d1f164_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_73e1720c-6d04-4906-81b7-27e18141d65b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_144cc91b-7959-409c-a69b-367f3bd3406a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c17a277a-3955-45d1-bf6b-675e3d88b173_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ce61bb49-ecd9-4ce3-8f02-03d8a08c7ed8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_46179d48-a29e-4b4a-a308-bce02d6e5814_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_eb1efd08-74c3-4101-99d6-c113d145277a_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_6922d6e4-6069-4f86-9e72-f5cef5d76169_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_95fb8e24-2747-4b52-a6f2-8877ba496f17_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cpix-20250319_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:13b9bc89-ef3b-478e-b901-8a57c671430d,g:31c95f9c-d6b6-4398-8ff0-d9ad9012d247-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="cpix-20250319.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://cumberlandpharma.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_81db3cb7-5483-4700-a08f-77bebf0627ab" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_DocumentType_81db3cb7-5483-4700-a08f-77bebf0627ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_51671ff8-d617-4fe5-9807-0ecd51e794bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_DocumentPeriodEndDate_51671ff8-d617-4fe5-9807-0ecd51e794bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_75f7e4b9-047f-4e0d-b6af-1c6fac0430c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_EntityRegistrantName_75f7e4b9-047f-4e0d-b6af-1c6fac0430c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_3264c49a-7c66-4608-a81e-4d0bb0334414" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_EntityCentralIndexKey_3264c49a-7c66-4608-a81e-4d0bb0334414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_70c597fa-a74a-4f69-8790-c95e68c3f131" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_AmendmentFlag_70c597fa-a74a-4f69-8790-c95e68c3f131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_71893297-e83c-4722-9d29-fdfbee4ce6af" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_EntityIncorporationStateCountryCode_71893297-e83c-4722-9d29-fdfbee4ce6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e40098a6-348f-4037-94f2-cd82af0d88d2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_EntityFileNumber_e40098a6-348f-4037-94f2-cd82af0d88d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_14868f64-2c74-417f-9035-e369fa25eb37" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_EntityTaxIdentificationNumber_14868f64-2c74-417f-9035-e369fa25eb37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_493b6ae1-febe-4a1c-89b7-17ecec3e6216" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_CityAreaCode_493b6ae1-febe-4a1c-89b7-17ecec3e6216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_ed914048-54c0-400c-bd5f-d88c4958fe7d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_LocalPhoneNumber_ed914048-54c0-400c-bd5f-d88c4958fe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_1ef992e7-1c59-4505-be3c-0b1a68fc31dc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_WrittenCommunications_1ef992e7-1c59-4505-be3c-0b1a68fc31dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_8cb9cdb5-f3d5-4c54-9b27-3c7f3fcfe547" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_SolicitingMaterial_8cb9cdb5-f3d5-4c54-9b27-3c7f3fcfe547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_e6f00d58-a002-4e9a-8b00-6d9af366a9bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_PreCommencementTenderOffer_e6f00d58-a002-4e9a-8b00-6d9af366a9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a6782333-7b22-4623-8600-8275113d880c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a6782333-7b22-4623-8600-8275113d880c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_4ec0f2d1-cdb0-4b31-b41d-b2d621a2c21a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_Security12bTitle_4ec0f2d1-cdb0-4b31-b41d-b2d621a2c21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ae91d066-59e9-4631-a94e-148f2f0a1683" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_TradingSymbol_ae91d066-59e9-4631-a94e-148f2f0a1683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0e72e648-c576-44df-9275-11513206aa3e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_SecurityExchangeName_0e72e648-c576-44df-9275-11513206aa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fdc37059-2967-48ca-884a-b9baecb08d3f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_EntityEmergingGrowthCompany_fdc37059-2967-48ca-884a-b9baecb08d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_4bcd47b7-4e8d-4145-a79f-124b92488951" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_EntityAddressAddressLine1_4bcd47b7-4e8d-4145-a79f-124b92488951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_78cf6c95-f4d3-4d25-82cf-792fdc7e820e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_EntityAddressCityOrTown_78cf6c95-f4d3-4d25-82cf-792fdc7e820e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e84dc5c7-9e99-4ff7-aeff-db208fbcfaef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_EntityAddressStateOrProvince_e84dc5c7-9e99-4ff7-aeff-db208fbcfaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_aeb9cdef-ec36-44fd-82da-f9647da9014c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3ca7bce2-e9eb-41db-9526-c2e55cf9e679" xlink:to="loc_dei_EntityAddressPostalZipCode_aeb9cdef-ec36-44fd-82da-f9647da9014c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !: 8H# 2(  A$! Q$!_\0
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M%?O'#\!?@;;C$'P:^%<6 !E/A_X4#$#IN;^R=Q/N2<]>M?SR?\%.M.L/A_\
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M[TXZAXNT;3[PQ0:I:7UB_GV=Q/"XFMI,)(2@5PC+^"O[*7PP_P"#@/\ :Y^
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M+:*5[+PGX9UD_,1'I?BFU:5N.BB[M[1#D\#+C\*^//%O["W[6WPZUJ"[\3?
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MOXV^+<7]K7-YHNL^/VT^Z\0Z3I,P7[/HD^JV-K:S:O':$-Y=]J DO'#!9)&
M%?)7_!5+XC>,OA7^QWXF\6^!?%/BSP;KH^)/P.T)]>\#O*GBN#1O$_QA\%^'
M_$-MHA@CEF:^U#1-1O[&%(HVED:XV1C>RFC"X1XK'4<%1JQFZU>%&G6E&:C^
M\:BGRR2FK7U5MO70G45.C*K*%E&+E*&E[1LWL[:][Z^F_P"B_ X&!GG'_P!;
M\*" >H!&/3/7T/;MT[9'>OS(_9UT[PO>?%30GTOQ_P#MXZC=VD%]>I8?&NV\
M:67P^NUAMSOAU636=.@L))"K;K.&257EE4; 2*_3C]*G%89X:I[)5'.346Y.
M#A9MI/W9-NUM?G;H.E452/,H\NMK73Z+733RZ[6W6B#';'X8_I287I@<?0FO
MAK_@GK\0/&/Q+^ OB;Q'XY\0:AXFURU_:/\ VK_"L&HZE*)KJ'P_X,_:.^)W
MA;POI0=5 %KHWA[2--TNR7&4M+2%"6*Y-#_@GA\1?&OQ-^$7Q+USQWXCU#Q-
MJNE?M(_'7PII][J4HFGM?#WAWQC-8Z+I43!5 M=.M%6"W0C*H,$GM=7 U*'U
MMRG%O"5*-.?*VG*56,G&UMDG![ZW:LGK:8UH3]E[NE6$W'RY$E^OSL?>AVCL
M/I@9/T%&%QD '/3MG_#W_/J*\0^-_P 'F^+>E:9$GQ+^*7PW?0#J5XMS\,?%
MEQX4N=4-Q;QJ(-7E@BE-Y;VY@$EM&P BDDE8'+FOSR_X)L_#OQQ\1_AEHGQN
M^('[1/[0'C+Q#HOQ;^,?A[^PM>^(-U=^$M3TGP3\2/%7A'1+;5=#%LD-V(]*
MTZT,Y9@9[E//8[R:JG@X5,'6Q3Q:A[&<*<J3IU'+FJJI*FHR2<;-0=VGI9+0
M'4E&M"E[-M2BVIWA91C9.Z;O?WM.5=[I:-?K[M R0 ">X !''J,'BEJ.5BL<
MA!PP1B..,A21]?<9Z#MUKX7_ .";?Q#\:?%3]D7P/XV^(/B+4?%7BG4/&OQM
ML+S6M4E$M[<6F@?&[XAZ!HT$CJJ[H]/T?3+#3X 5^2WM8E/3)YZ=&<\/6KW2
M5*=*#3U;=7GY;+2R7([K_AS1R2G"%M9J37ERV;^^Y]U$!N#SWQ_G_(]J%VJ,
M#&/3L?;CC\!S7P?^W#\:OB7X"_X4+\'?@[JNG^%/B'^TM\5!\-M/\?ZK9QZA
M:^ ]!TW0-0\3>*==L[&X!M+WQ$=*T]K/P[:WFZV:_G\^6*9;?87P?L5:]I9T
M76] _:N_:7L?&^FZA87^HZ_JWCF/Q)I&OI;W"37NGZGX-U6QE\/'3[^,26_V
M>"VB^RQR#[.RLBFMX8*"H4J]?%1H1Q'/["/)4FY*G+DE4?(FHQ=2+@MVW=VL
M9NHW4E"%-SY'%3=U&SDHR23=MDU)I-+?5.Y]W!0.@ .>,<#GCI[X'^32_P">
MA/\ ('_/2F(&5%5F,C*J@N0%WD#!8@< DC) X&>*_-']N#XK>//%_CSX8_L7
M? ?XE2_"WXH?%"WOOB+\1_BAI<]FFJ?";X*^#+A&EU&S-X3;Q>(/B%XM73/!
MF@QRJS'3V\2WPB*V(:HP>$JX[$*A3:5U*=2K)2E"E2IQ3G4FXIRY8Q5[V;V2
M3Z55J1H4W)]+*,59.3DU:*5TKZZ??W/TPVC.2!D9'Z]/J#^N:7ZU\8_L-?M$
M:I\?O@X]OX[>QMOCA\(/$6I?"'X[:-92Q/';?$/PB4MI]?L41F8^'_'&F-8>
M,/#UR!Y,NGZPL$<CO:S;?6/VH_$.L^$?V:/VA?%?AS4;C2/$/ACX(?%;Q#H.
MJVC;+O3-9T;P)KVHZ9J%JYR%N+.]MH+F%B"!)&I(-*KA*M'%_5*MXU(U52E=
M/E]YI1FD]>62<9)]5;JPC5A*E[6.L7'FTMOU3\T]'H]MF>ZX!Z@'T[X'8 XZ
M>GIT'%!4-G(7UZ ?Y/TY].>:^?\ ]E#Q+KGC+]F#]GCQ=XGU.XUGQ'XG^"OP
MQU[7M6O&#W>IZQJW@W1[[4;^Y8 ;I[N[N))YF  ,CL0!DBO?)_,$,IBQY@1O
M+S]TO@[ Q .%+8S_ )!QG"4:TJ=[.$W3YDVDVGRWUVBM;W5[>EBH\LH1G:Z<
M5+97U5];]>N_S),@'' S[\D]ACT Z?EZ4M?SW^!OB#J6DW]RG[=/QT_:P_9F
M^/TOQ,U&.T\8NVLZ5^S0^GR^+9(_">D>%_$>DZ7JOPQMO#VL:.MA9/;^-+_1
M]0>:ZE$^)\2#^@JV97@A=)A.CQ1LDRLK+*C1J5E5U)5UD&'#*2K;LJ<8KLQN
M E@734JGM5--J<835.37*_<J/W:BL]7&S6S2(HUE5O9<K6R;7-;NUNM>Y-11
M17";!1110 56NK.TO86@O+:"Z@<%6BN8DGC8$;2&2574@C@@@@]\U9HH \&\
M3?LN?LZ>,9I;KQ)\$_AGJEW<-NGO9O"&BI>RGLSW<-I'<,V.-QDS@G!%?QM?
M\%B/CM\:OV/?V_!\$/V7_BQ\0_@7\)+SX0> ?&%U\/\ X;^+M=\,^&I_%&M:
MIXLT_5=<ET[3KV*-M0OK+2-,MKB?[SPV-LAXC7']SU?P/_\ !?\ T35_$?\
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th"><div>Mar. 19, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 19,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CUMBERLAND PHARMACEUTICALS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001087294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1765329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-0068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPIX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1600 West End Avenue, Suite 1300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Nashville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">37203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .Z(<UI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( .Z(<UKH@H<)\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( .Z(<UI8,GQ[9@0  *H0   8
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
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M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M" #NB'-:EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #NB'-:1L=-2)4
M  #-    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( .Z(<UKH@H<)\@   "L"   1              "  <,   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( .Z(<UJ97)PC$ 8  )PG   3
M          "  >0!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M[HAS6E@R?'MF!   JA   !@              ("!)0@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .Z(<UJ?H!OPL0(  .(,   -
M          "  <$,  !X;"]S='EL97,N>&UL4$L! A0#%     @ [HAS6I>*
MNQS     $P(   L              ( !G0\  %]R96QS+RYR96QS4$L! A0#
M%     @ [HAS6APX9>H_ 0  / (   \              ( !AA   'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( .Z(<UHD'INBK0   /@!   :
M      "  ?(1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( .Z(<UIED'F2&0$  ,\#   3              "  =<2  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "$4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="cpix-20250319.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cumberlandpharma.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="cpix-20250319.htm">cpix-20250319.htm</File>
    <File>cpix-20250319.xsd</File>
    <File>cpix-20250319_lab.xml</File>
    <File>cpix-20250319_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "cpix-20250319.htm": {
   "nsprefix": "cpix",
   "nsuri": "http://cumberlandpharma.com/20250319",
   "dts": {
    "inline": {
     "local": [
      "cpix-20250319.htm"
     ]
    },
    "schema": {
     "local": [
      "cpix-20250319.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "cpix-20250319_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cpix-20250319_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20250319.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "cpix-20250319.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Information [Line Items]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://cumberlandpharma.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001628280-25-013875-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-25-013875-xbrl.zip
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M^!CF<HIF"YA\B<#^GOE1N.!1FE:I;56KFF'4&B\I]-]H=4UA=6^2'.\Y2DA
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MGA4BBF?.108IN-L5JYIA.9D_#Q''(#MF'74_#)!E&SITW)BWO#L8?UVP#Z.
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MDTPOYD,(JH2L__&D<_YU<,M7S&ZG_GFS)K/?6U)YD[]2RF1=("]XJ+:WZH#
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MR?).PY69S264I*OU+.CX[X[4K&10F,'78$>[!]AQ:R*7H+^2!E1+*+PS\7R
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M0(=QR\EW'H?)8<9=RE$0OC#]%XWK7E7Y=+OQ=;ER:'ED>0Z912J$<@K<685
M^^,D$G,\-W(4]P_<#2-^QMW'YX,WDYO^W4U8N^H2^P=L#+7 G/9$(=,Y*!43
M6,I7P'G&I6"Y<Q(GN?&_]3I, S-N.(Z&<A9-QW<;;"Y)RO]JZNMV38O;UE6W
MJQ2#U(RV1,+F&I0)5/48Y<!;[S!X9J*<X@G%#YT/$\;L.X[C@9V%/HYC) 9V
M]Q]G185\I7R(2GN*'TTD8%0&3ML$7"AOA3+&9N,>93[I>I@V9MR*G ;4.2FC
M:ZY^:"[JZVJE34AYL+215E&"BB*CNC<DT%:0[C4:P<:M(T\X'O8"U(R[E%,
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MXBV!L++&)(%4',NQ\.WZW8(KHW3:*Z%R[25=%H%'W,N>4>.2H2RU@A#!*7Q
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M%@=[@^X!_MKRDPT_A/]6X ?^[PS^#U!+ 0(4 Q0    ( .Z(<UK# U9*"@\
M +5I   1              "  0    !C<&EX+3(P,C4P,S$Y+FAT;5!+ 0(4
M Q0    ( .Z(<UK,LLUR?0(  &8'   1              "  3D/  !C<&EX
M+3(P,C4P,S$Y+GAS9%!+ 0(4 Q0    ( .Z(<UJ2<+,6.PH  (Q5   5
M          "  >41  !C<&EX+3(P,C4P,S$Y7VQA8BYX;6Q02P$"% ,4
M" #NB'-:*5L@&\,&  !#,0  %0              @ %3'   8W!I>"TR,#(U
M,#,Q.5]P<F4N>&UL4$L! A0#%     @ [HAS6D!/-NII$P  U6   !X
M         ( !22,  &1M9'!R97-E;G1A=&EO;F%T;61A<F5L96%S+FAT;5!+
4!08     !0 % % !  #N-@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>cpix-20250319_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cpix-20250319.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001087294</identifier>
        </entity>
        <period>
            <startDate>2025-03-19</startDate>
            <endDate>2025-03-19</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001087294</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-03-19</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">CUMBERLAND PHARMACEUTICALS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">TN</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-33637</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">62-1765329</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">1600 West End Avenue, Suite 1300</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Nashville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">TN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">37203</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">615</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">255-0068</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">CPIX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
